The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Janssen Oncology
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Wassim Abida
Honoraria - CARET
Consulting or Advisory Role - Clovis Oncology
Research Funding - AstraZeneca; Clovis Oncology; GlaxoSmithKline (Inst); Zenith Epigenetics
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Alan Haruo Bryce
No Relationships to Disclose
 
Arjun Vasant Balar
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst)
 
Igor Dumbadze
No Relationships to Disclose
 
Robert W. Given
No Relationships to Disclose
 
David Morris
Consulting or Advisory Role - Astellas Pharma; Dendreon; GenomeDx; Janssen; Myriad Pharmaceuticals; Pacific Edge Biotechnology
Speakers' Bureau - Astellas Pharma; Dendreon; GenomeDx; Janssen; Myriad Pharmaceuticals; Pacific Edge Biotechnology
Research Funding - Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Janssen; Myriad Pharmaceuticals
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio
Expert Testimony - Celgene; sanofi
 
Charles H. Redfern
No Relationships to Disclose
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Ferring; Janssen Research & Development; Merck; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Asterias Biotherapeutics; Ferring; Onclive; Physicans' Education Resource; WIRB-Copernicus Group
 
Simon Paul Watkins
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology; United Health Group
 
Andrew Simmons
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Consulting or Advisory Role - Redwood Bioscience
 
Luke Passler
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Tony Golsorkhi
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Simon Chowdhury
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Research Funding - Johnson & Johnson; Sanofi